Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg-Reference-Cited by-同舟云学术

Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg

Published:2024-01-25 Issue:4 Volume:29 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Ernst Corinna¹²^ORCID,Bejko Dritan²,Gaasch Leo³,Hannelas Emilie³,Kahn Isaline³,Pierron Charlotte³,Del Lero Nesrine³,Schalbar Claude³,Do Carmo Elsa³,Kohnen Michel⁴,Andlauer Emmanuelle⁵,Hublart Pauline²,Masi Silvana²,de la Fuente Garcia Isabel³,Vergison Anne²,Mossong Joël²^ORCID

Affiliation:

1. ECDC Fellowship Programme, Field Epidemiology path (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

2. Health Directorate, Luxembourg

3. National Center for Pediatrics, Centre Hospitalier de Luxembourg, Luxembourg

4. Microbiology department, Centre Hospitalier de Luxembourg, Luxembourg

5. Hospital Pharmacy department, Centre Hospitalier de Luxembourg, Luxembourg

Abstract

After Luxembourg introduced nirsevimab immunisation against respiratory syncytial virus (RSV), estimated neonatal coverage was 84% (1,277 doses/1,524 births) in 2023. That year, paediatric RSV-related hospitalisations, especially concerning infants < 6 months old (n = 72) seemed to decrease compared to the same period in 2022 (n = 232). In 2023, hospitalised children’s mean age increased (14.4 months vs 7.8 months in 2022; p < 0.001) and hospital-stay length decreased (3.2 days vs 5.1 days; p < 0.001). In infants < 6 months old, intensive-care unit admissions appeared to drop (n = 28 vs 9). This suggests that nirsevimab prophylaxis reduced severe RSV infections, particularly in infants < 6 months old, thereby alleviating healthcare strain.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Reference11 articles.

1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.;Li;Lancet,2022

2. Early and intense epidemic of respiratory syncytial virus (RSV) in Denmark, August to December 2022.;Munkstrup;Euro Surveill,2023

3. Respiratory syncytial virus infections - recent developments providing promising new tools for disease prevention.;Broberg;Euro Surveill,2023

4. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.;Drysdale;N Engl J Med,2023

5. Nirsevimab for prevention of RSV in healthy late-preterm and term infants.;Hammitt;N Engl J Med,2022

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulatory markers and therapies for the management of infant respiratory syncytial virus infection;Expert Review of Anti-infective Therapy;2024-09-13

2. Nirsevimab and Acute Bronchiolitis Episodes in Pediatric Emergency Departments;Pediatrics;2024-09-11

3. Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children;The Lancet;2024-09

4. New Vaccines for Chronic Respiratory Patients;Archivos de Bronconeumología;2024-09

5. The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study;Frontiers in Public Health;2024-08-16